logo-loader
viewQ BioMed Inc.

Full interview: Q BioMed shares soar on FDA greenlight to begin manufacturing Strontium-89

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive the biotech is 'extremely pleased' with the FDA's decision to green light the production of its drug Strontium-89 Chloride with its contract manufacturer IsoTherapeutics Group LLC.

Corin says IsoTherapeutics Group will produce the non-opioid cancer bone pain drug to treat bone pain associated with a variety of metastatic cancers. Shares of the company soared 343% Wednesday (November 20).

Quick facts: Q BioMed Inc.

Price: 1.46 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $24.41 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed CEO sees significant capital funding for next 3 years

Q BioMed Inc (OTCMKTS:QBIO) CEO Denis Corin tells Proactive announced that its technology partner, Mannin Research Inc, has received a $7.5 million grant from the German state of Saxony to fund the development of its glaucoma therapies. Corin talked about how the two partners plan to...

1 month ago

2 min read